Tenaya Therapeutics, Inc. 8-K Filing
Ticker: TNYA · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1858848
| Field | Detail |
|---|---|
| Company | Tenaya Therapeutics, Inc. (TNYA) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Pages | 5 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $1.20, $1.50, $1.128, $60 million |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Tenaya Therapeutics, Inc. (ticker: TNYA) to the SEC on Dec 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select); $1.20 ("Units"), at a public offering price of $1.20 per Unit, consisting of one share of th); $1.50 (of Common Stock at an exercise price of $1.50 per share that is exercisable for a per); $1.128 (he Units from the Company at a price of $1.128 per share. All of the Units in the Offe); $60 million (ompany are expected to be approximately $60 million. The Offering is expected to close on D).
How long is this filing?
Tenaya Therapeutics, Inc.'s 8-K filing is 5 pages with approximately 1,631 words. Estimated reading time is 7 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,631 words · 7 min read · ~5 pages · Grade level 12.7 · Accepted 2025-12-12 16:30:17
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select
- $1.20 — "Units"), at a public offering price of $1.20 per Unit, consisting of one share of th
- $1.50 — of Common Stock at an exercise price of $1.50 per share that is exercisable for a per
- $1.128 — he Units from the Company at a price of $1.128 per share. All of the Units in the Offe
- $60 million — ompany are expected to be approximately $60 million. The Offering is expected to close on D
Filing Documents
- d67398d8k.htm (8-K) — 36KB
- d67398dex11.htm (EX-1.1) — 241KB
- d67398dex41.htm (EX-4.1) — 68KB
- d67398dex51.htm (EX-5.1) — 11KB
- d67398dex991.htm (EX-99.1) — 10KB
- g67398dsp01.jpg (GRAPHIC) — 6KB
- g67398dsp02.jpg (GRAPHIC) — 2KB
- 0001193125-25-317642.txt ( ) — 594KB
- tnya-20251211.xsd (EX-101.SCH) — 3KB
- tnya-20251211_lab.xml (EX-101.LAB) — 18KB
- tnya-20251211_pre.xml (EX-101.PRE) — 11KB
- d67398d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company's expectations regarding the size, terms, timing and completion of the Offering and the expected gross proceeds. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the Offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the Offering. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 10, 2025. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. 1.1 Underwriting Agreement between the Company, Leerink Partners LLC and Piper Sandler & Co., dated as of December 11, 2025. 4.1 Form of Warrant. 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included with the opinion filed as Exhibit 5.1). 99.1 Press Release dated December 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Jennifer Drimmer Rokovich Jennifer Drimmer Rokovich General Counsel and Secretary Date: December 12, 2025